Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to therapy is the primary treatment challenge associated with relapse and recurrence, especially in elderly patients. The foremost goal in the third-line treatment of multiple myeloma is extending patients’ survival. The mainstays of treatment are agents that affect the immune system, such as Celgene’s Revlimid and Pomalyst / Imnovid used in combination with the generic corticosteroid dexamethasone. The launch of the proteasome inhibitor Kyprolis (Amgen / Ono Pharmaceutical) and the emergence of novel drugs including Bristol-Myers Squibb / AbbVie’s Empliciti and Janssen’s Darzalex are impacting treatment choices in the third-line setting. However, in the absence of a uniform treatment regimen, the choice of third-line therapy for multiple myeloma patients is varied.
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European hematologist-oncologists fielded in December 2018
Key companies: Janssen, Celgene, Amgen / Ono Pharmaceutical, Bristol-Myers Squibb / AbbVie
Key drugs: Darzalex, Revlimid, Empliciti, Ninlaro, Kyprolis, Pomalyst / Imnovid
Already a Client? Log in to access this report.
Snigdha is a lead analyst in the oncology team at Decision Resources Group working on multiple oncology indications including non-small cell lung cancer and multiple myeloma. Snigdha holds a in infectious diseases from the Indian Institute of Chemical Biology, Jadavpur University, Kolkata, India. She went on to pursue her postdoctoral fellowship from the Mucosal Immunology lab of National Institute of Immunology, New Delhi, India and has published in several peer-reviewed journals. Prior to joining DRG, Snigdha was a subject matter expert in indications including immuno-oncology and autoimmunity. Her role dealt with the generation of framework-based scientific analyses for client projects. In her previous organizations, she was involved in the planning and execution of the IND enabling preclinical studies. She has been instrumental in the stage-up of two small molecules associated with immuno-oncology and inflammatory disease at BioXcel Therapeutics and Daiichi Sankyo Pharma India Pvt. Ltd. respectively.